GH
Guardant Health Inc
7월 27일 2:45 PM ET (한국 7/28 03:45)
$147.33
-2.87 ▼ -1.91%
가드란트 헬스(GH) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
시가총액
$19.5B
미드캡
P/E
-
배당수익률
없음
52주 위치
80%
저점 +265% · 고점 -15%
애널리스트
적극 매수
B+
Fundamental health
vs. 미분류 대형주· based on 2 axes
수익성 산출 불가 (적자)
성장 Top 35%
밸류에이션 데이터 부족
재무 안정 Top 19%
| Index | - | P/E | - | EPS (ttm) | -3.4 | Insider Own | 4.01% | Shs Outstand | 131.5M | Perf Week | -5.48% |
| Market Cap | 19.54B | Forward P/E | - | EPS next Y | 34.82% | Insider Trans | -12.6% | Shs Float | 127.3M | Perf Month | 7.57% |
| Enterprise Value | 20.14B | PEG | - | EPS next Q | -0.76 | Inst Own | 104.26% | Short Float | 9.54% | Perf Quarter | 67.67% |
| Income | -0.43B | P/S | 18.09 | EPS this Y | 13.31% | Inst Trans | 3.79% | Short Ratio | 4.61 | Perf Half Y | 25.62% |
| Sales | 1.08B | P/B | - | EPS next 5Y | - | ROA | -26.58% | Short Interest | 12.14M | Perf YTD | 44.24% |
| Book/sh | -1.38 | P/C | 17.72 | EPS past 3/5Y | 19.67% -4.99% | ROE | - | 52W High | -15.37% ($174.08) | Perf Year | 223.87% |
| Cash/sh | 8.32 | P/FCF | - | Sales past 3/5Y | 29.75% 27.92% | ROIC | -28.97% | 52W Low | 265.08% ($40.35) | Perf 3Y | 298.4% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -0.63% | Gross Margin | 64.9% | Volatility(W/M) | 4.62% 5.07% | Perf 5Y | 23.77% |
| Dividend TTM | - | EV/Sales | 18.64 | Sales Y/Y TTM | 39.56% | Oper. Margin | -41.38% | ATR (14) | 7.46 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 4.39 | EPS Q/Q | -11.14% | Profit Margin | -40.1% | RSI (14) | 48.71 | Recom | 1.45 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.68 | Sales Q/Q | 48.26% | SMA20 | -6.3% ($157.24) | Beta | 1.61 | Target Price | $174.61 |
| Payout | - | Debt/Eq | - | Earnings | 2026/7/30 | SMA50 | 7.64% ($136.87) | Rel Volume | 0.71 | Prev Close | $150.2 |
| Employees | 2506 | LT Debt/Eq | - | EPS/Sales Surpr. | -5.46% 8.07% | SMA200 | 40.09% ($105.17) | Avg Volume(3M) | 2.64M | Price | $147.33 |
| IPO | 2018/10/4 | Option/Short | Yes/Yes | Trades | 93860 | Volume | 1,884,675 | Change | -1.91% |
Quarterly earnings trend SEC filings · USD
24.6
24.9
24.12*
25.3
25.6
25.9
25.12*
26.3
Revenue Net income 최근 분기: 매출 $302M (YoY +48%) · 순이익 $-112M (YoY -18%)
* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red
Guardant Health Inc (GH) Investment Analysis
What kind of company is Guardant Health Inc?
가드란트 헬스(GH)
Healthcare · Diagnostics & Research
#622 by Market Cap — Mid-Cap
🧬 A precision diagnostics company that offers blood-based cancer genomic testing. Its core technology is liquid biopsy, which analyzes cancer-related genetic mutations from blood samples, and it provides cancer diagnostics to help guide treatment choices as well as early cancer screening tests. It is one of the leading companies in the liquid biopsy-based cancer diagnostics space.
Learn more about Guardant Health Inc →Market Cap
$19.5B
Approx. KRW 26.8 trillion
⚖️ 7% of Samsung Electronics
Market Cap Rank622
Employees2,506people
IPO2018/10/04
Current Price$147.33 ≈ 201,842원
Key Events
⏰ Upcoming events
🔔 Earnings release D-3
7월 30일 (목) · 장 마감 후
예상 EPS $-0.76
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🔔 Earnings release 2026년 5월 7일 (목) · 장 마감 후 EPS -5.5% 매출 +8.1%
🔔 Earnings release 2026년 2월 19일 (목) · 장 마감 후 EPS -30.4% 매출 +3.3%
Is it profitable?
Financially sound but profitability is low
Losses or thin margins — early-stage growth or weakening competitiveness
Profitability — How efficiently it makes money
Operating Margin
Profit kept from selling products and services (higher is better)
-41.4%
✓ 적자
Net Margin
Share of revenue left after taxes and interest are paid
-40.1%
✓ 적자
Gross Margin
Profit after subtracting raw-material costs only (signals product competitiveness)
64.9%
✓ 우수
ROA
Annual earnings relative to total company assets
-26.6%
✓ 적자
ROIC
Return generated per dollar invested in the business
-29.0%
✓ 적자
Financial health — Debt & liquidity burden
Current Ratio
Liquid assets available to cover liabilities due within a year
4.68
✓ 우수
Quick Ratio
Liquid assets excluding inventory, available for immediate use
4.39
✓ 우수
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).
What's the outlook?
Positive Outlook
Price targets, growth, and valuation are favorable
애널리스트 목표가
$174.61
현재가 대비 +18.5%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
내년 EPS 예상 성장률
+34.8%
💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.
Did earnings meet expectations?
Average Earnings Performance
Mixed beats and misses
1
예상 상회
0
예상 부합
1
예상 하회
50%
상회 비율
-0.8%
평균 서프라이즈
2026.05.07
상회
실적 $-0.45 · 예상 $-0.47 +5.0%
2026.02.19
하회
실적 $-0.50 · 예상 $-0.47 -6.5%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.
Is it growing?
Strong Growth
Above the industry average, both historically and going forward
Healthy, Balanced Growth EPS and revenue are both growing steadily — a sustainable growth profile
🔮 How much will it grow? (analyst forecasts)
This Year's EPS Outlook
Projected EPS growth rate for this year
+13.3%
양호
Next Year's EPS Outlook
Projected EPS growth rate for next year (analyst consensus)
+34.8%
양호
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
+19.7%
양호
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
-5.0%
평균
Past 5-Year Revenue
How much revenue grew over the past 5 years
+27.9%
우수
⚡ Short-term momentum
QoQ Revenue
Revenue change from the previous quarter (short-term momentum)
+48.3%
우수
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.
New to investing terms? Look it up in the financial dictionary →
Has the stock risen over the long term?
Long-term weakness — -44%p below the market
GH +23.8% · S&P 500 +68.0%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
-44.2%p
Significantly behind the market
vs Health Care (XLV)
+0.1%p
roughly in line with the sector average
1-year basis
vs S&P 500
+207.4%p
well ahead of the market
vs Health Care (XLV)
+204.1%p
well ahead of the sector average
Rank among peers
5-year return Top 25% Based on 15 peers
1-year return Top among peers Based on 15 peers
Current position within 52-week range
Low (-265.1%p) High (-15.4%p)
Current price is 265.1% above the 52-week low and 15.4% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-30.5%
Annualized volatility
59.2%
Technical Indicators
Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series
Price · Bollinger Bands · Ichimoku Cloud
- close
- BB Upper
- BB Mid
- BB Lower
- Tenkan
- Kijun
- Cloud (SpanA/B)
Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →
Current diagnosis · 2026-07-24
Downtrend zone
Current price $147.33 below the midline ($157.24). Normal downward flow. Inside the Ichimoku cloud (neutral).
MACD (12 · 26 · 9) Expand ▼
An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →
Current diagnosis · 2026-07-24
Neutral zone — weak trend
MACD 3.761 · Signal 6.658 · Hist -2.897. Weak directional bias.
RSI(14) · Stochastics %K(14) Expand ▼
RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →
Current diagnosis · 2026-07-24
Bearish zone
RSI 48.7 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 9.5.
※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.
Is it attractive at this price?
Pricier than peers in its industry
Pricey on Vs. Sales
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
Vs. Sales Pricey
🧾 Vs. Sales
PSR Price-to-Sales Ratio
Market cap vs. revenue — lower is cheaper relative to sales
18.09x
✓ Very pricey
Analyst target price (reference)
$174.61 vs. current price +18.5%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Diagnostics & Research 대형주
Who owns it?
Ownership flow shows some pressure
Insider net selling -12.6% · Institutional net buying +3.8% · Short interest moderate 9.5% · Short interest up +0.8pp over last 90d
📈 Recent trading flow (6 months)
🧑💼 Insiders (executives & directors)
-12.6%
Insiders large net selling
🏦 Institutions (funds & investors)
+3.8%
Institutions net buying
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 104.3%
Institution-led, stable structure
🧑💼 Insiders 4.0%
Typical level
👤 Retail investors (estimated) 0.0%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
9.5%
Moderate
Past 90 days 📈 +0.8%p increase
Short interest days to cover
4.6 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 131.5M주
Float (tradable shares) 127.3M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.
ETFs holding GH
ETFs with the highest weightings · 10 total shown
* Based on official quarterly filings. Latest disclosure; actual current weights may differ.
How much does it pay in dividends?
This company does not pay a dividend
It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.
Compare Industry Peers
💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
| Stock | Market Cap | PER | PBR | ROE | Dividend Yield | Change |
|---|---|---|---|---|---|---|
| GH This Stock | $19.5B | - | - | - | - | -1.9% |
LLY | $1.13T | 43.0 ▼ | 36.2 ▼ | 107.64% ▲ | 0.58% ▼ | +0.9% |
JNJ | $634.1B | 30.5 ▼ | 7.5 ▼ | 25.74% ▲ | 2.04% ▲ | +1.6% |
ABBV | $458.2B | 127.9 ▼ | - | 15221.82% ▲ | 2.65% ▲ | +0.9% |
UNH | $382.1B | 27.1 ▼ | 3.9 ▼ | 12.49% ▲ | 2.15% ▲ | -0.7% |
MRK | $323.7B | 36.9 ▼ | 7.1 ▼ | 18.97% ▲ | 2.49% ▲ | +0.5% |
| Sector Avg | - | 25.8 | 2.7 | -48.83% | 1.25% | - |
Derivative ETFs for GH
Leveraged, inverse, and covered call ETFs based on the underlying asset
9 derivative ETFs based on GH (Leverage 2 · Inverse 2 · Covered Call 5)
These are based on the same underlying asset but carry a completely different risk and return profile. Please review the warning below first.
ℹ️ What is a Derivative ETF?
These are special ETFs that amplify, reverse, or monetize the price movement of an underlying ETF or security. Leveraged ETFs aim for 2–3× the daily move, Inverse ETFs target opposite-direction returns, and Covered Call ETFs generate monthly income from option premiums.
⚠️ Caution: Long-Term Holding
Leveraged and inverse ETFs track only the daily return. With high volatility, holding them for longer periods causes cumulative volatility decay—returns diverge further from the underlying index. They are meant for short-term trading.
Leverage 2 ETFs that move 2-3x with GH (high volatility)
Inverse 2 Profits when GH falls (downside bet)
Covered Call & Options 5 A strategy that generates monthly dividend income through covered calls
LQTI
FT Vest Investment Grade & Target Income ETF
-0.37%
$281M
HYGW
iShares High Yield Corporate Bond BuyWrite Strategy ETF
+0.02%
$112M
HYTI
FT Vest High Yield & Target Income ETF
+0.13%
$89M
BFEW
FT Vest Laddered U.S. Equity Equal Weight Buffer ETF
+0.50%
$2M
HYGM
Amplify HYG High Yield 10% Target Income ETF
+0.00%
FAQ
What kind of company is 가드란트 헬스(GH)?
가드란트 헬스(GH) belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of GH?
The market cap of GH is approximately $19.5B, ranking 622 within its sector.
What is the 52-week high and low for GH?
GH has recorded a 52-week high of $174.08 and a low of $40.35.
면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.